MP76-16 PATTERNS OF MEDICAL MANAGEMENT OF OVERACTIVE BLADDER (OAB) AND BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE US: WHO DOES BETTER?

Abstract

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life and Shared Decision Making IV1 Apr 2017MP76-16 PATTERNS OF MEDICAL MANAGEMENT OF OVERACTIVE BLADDER (OAB) AND BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE US: WHO DOES BETTER? Jennifer Anger, Howard Goldman, Xuemei Luo, Martin Carlsson, Douglass Chapman, Kelly Zou, Fady Ntanios, David Russell, Canan Esinduy, and J. Quentin Clemens Jennifer AngerJennifer Anger More articles by this author , Howard GoldmanHoward Goldman More articles by this author , Xuemei LuoXuemei Luo More articles by this author , Martin CarlssonMartin Carlsson More articles by this author , Douglass ChapmanDouglass Chapman More articles by this author , Kelly ZouKelly Zou More articles by this author , Fady NtaniosFady Ntanios More articles by this author , David RussellDavid Russell More articles by this author , Canan EsinduyCanan Esinduy More articles by this author , and J. Quentin ClemensJ. Quentin Clemens More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2144AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES BPH and OAB are highly prevalent conditions that place a large burden on the US health care system. Medical management is the mainstay of therapy for both conditions, but few datasets are available that analyze patterns of medication usage and long-term persistence. This study analyzes patterns of prescription medication usage for incident BPH in men and incident OAB in men and women using US observational data. METHODS Truven Health MarketScan® Commercial and Medicare Supplemental Research databases include de-identified medical claims and prescription drug claims for individuals in the US with employer-sponsored health insurance, as well as individuals with Medicare supplemental coverage. The data are pooled from diverse points of care, including large employers, managed care organizations, hospitals, and public organizations, thus providing greater generalizability than single payer databases. Men age 18+ had incident BPH with 2 diagnoses of BPH =30 days apart and no BPH diagnosis for 1 year prior, based on ICD-9 codes for BPH, bladder neck obstruction, urinary retention, and incomplete bladder emptying. Men and women age 18+ were diagnosed similarly with incident OAB, based on ICD-9 codes for OAB symptoms (urinary frequency, urgency, nocturia, urge incontinence). Other criteria included continuous enrollment for 1 year before and 6 months after the first diagnosis date. Medication continuation (persistence), switching, and discontinuation were analyzed through September 30, 2013. RESULTS 31,701 women and 7,208 men were prescribed OAB medication; 69,079 men were prescribed medication for BPH (Table 1). Medication persistence was much higher overall for BPH than OAB (56% vs 34%, respectively), and was highest among men with BPH age 65+ (62%). Patients age 18-64 were less likely to continue medication than older adults (age 65+) for both BPH and OAB. CONCLUSIONS Persistence was higher with BPH than OAB medications overall, likely reflecting a combination of better efficacy and tolerability of BPH medications. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1019 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Jennifer Anger More articles by this author Howard Goldman More articles by this author Xuemei Luo More articles by this author Martin Carlsson More articles by this author Douglass Chapman More articles by this author Kelly Zou More articles by this author Fady Ntanios More articles by this author David Russell More articles by this author Canan Esinduy More articles by this author J. Quentin Clemens More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...